Equities

Zhaoke Ophthalmology Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Zhaoke Ophthalmology Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.46
  • Today's Change0.00 / 0.00%
  • Shares traded42.50k
  • 1 Year change+94.38%
  • Beta1.4468
Data delayed at least 15 minutes, as of Feb 16 2026 03:54 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zhaoke Ophthalmology Ltd is an investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs and products. The product pipelines primarily include NVK002 (Atropine) for myopia, CsA Ophthalmic Gel for DED and TAB014 (Bevacizumab) for wAMD. The products are primarily uses to treat eye diseases across both the front and the back of the eye, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), glaucoma and corneal epithelial dysfunction (CED). The Company conducts its business in the domestic market and overseas markets.

  • Revenue in HKD (TTM)40.00m
  • Net income in HKD-314.86m
  • Incorporated2020
  • Employees270.00
  • Location
    Zhaoke Ophthalmology LtdNo. 1 Meide 3rd Road, Pearl RiverIndustrial Park, Nansha DistrictGUANGZHOU ChinaCHN
  • Phone+86 2 039062888
  • Websitehttps://www.zkoph.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
3D Medicines Inc507.27m-190.63m1.05bn183.00--1.29--2.06-0.7781-0.77812.073.140.37287.536.782,655,869.00-14.79---21.47--92.11---39.68--1.59--0.205---29.81--65.19------
Transcenta Holding Ltd10.64m-301.33m1.05bn171.00--1.30--98.49-0.7437-0.74370.02631.800.00750.37930.492757,844.45-21.21-32.48-30.08-41.1334.7622.08-2,831.15-1,072.370.4387-408.750.2437---79.09-23.9137.24---60.12--
Meilleure Health Intrntnl Indu Grp Ltd38.10m39.17m1.08bn49.0027.600.8898--28.440.00960.00960.00930.29780.02230.03630.9608828,173.902.282.742.603.0272.6447.18102.2728.592.39--0.221141.83-60.81-26.41-20.45---1.03--
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd1.05bn207.00m1.13bn798.005.470.57744.711.080.36950.36951.873.500.36982.303.341,407,584.007.307.4610.5410.4578.9577.8019.7420.451.42--0.042244.004.716.4124.324.95-8.31--
Beijing Biostar Pharmaceuticals Co Ltd-100.00bn-100.00bn1.37bn147.00------------------------------------------------7.85--24.19------
Dawnrays Pharmaceutical (Holdings) Ltd1.26bn199.64m1.82bn1.12k9.130.48676.151.440.13260.13260.83622.490.28092.477.961,064,644.004.3610.985.0713.7545.7655.5215.5332.764.21--0.002831.01-7.892.2273.2917.2017.132.69
Cutia Therapeutics283.20m-534.29m1.86bn298.00--1.92--6.56-1.70-1.700.90132.670.19082.555.57850,454.10-36.00---44.42--34.92---188.66--2.92--0.2774--103.17--77.91------
Zhaoke Ophthalmology Ltd40.00m-314.86m1.90bn270.00--0.979--47.40-0.5691-0.56910.07243.530.01591.389.25136,057.50-12.50-38.02-14.65-41.7949.28---787.13-4,412.894.36-29.830.1373--269.73--38.32--18.80--
Jbm (Healthcare) Ltd812.98m216.39m2.29bn412.0010.502.138.262.820.26570.26570.99841.310.51113.765.052,913,918.0014.096.5717.007.8356.7647.8227.5616.602.41--0.248653.4020.6515.4451.2036.9035.96--
Hangzhou Jiuyuan Genetic Biopharm Co Ltd1.48bn139.63m2.31bn1.63k14.821.3012.421.570.64640.64647.237.360.75091.552.17958,496.207.10--8.88--81.67--9.45--4.0346.310.1058--6.35--15.72------
Golden Throat Holdings Group Co Ltd1.11bn303.31m2.35bn842.007.751.726.902.120.41030.41031.501.850.4672.295.321,268,143.0012.7811.7121.0216.7576.4273.0827.3725.871.7321.950.361694.6723.268.2527.3713.71-12.2734.38
Essex Bio-Technology Ltd1.73bn313.18m2.52bn1.43k8.081.116.811.450.55080.55083.054.010.55962.962.841,196,360.0010.1010.2813.5613.6289.5087.7318.0518.701.82--0.113517.49-3.875.4711.610.3101-7.477.14
Jacobson Pharma Corporation Ltd1.53bn302.58m2.54bn1.79k8.361.145.631.660.15190.15190.76981.120.42992.549.06876,757.008.484.8310.296.1744.3041.2619.7314.850.902310.210.28657.097.430.069143.097.0524.0914.87
SinoMab Bioscience Ltd0.00-163.29m2.70bn61.00--8.53-----0.1508-0.15080.000.22850.00----0.00-18.46-22.26-24.62-25.68-------3,832.94---7.820.6265--48.42--23.85---0.376--
Data as of Feb 16 2026. Currency figures normalised to Zhaoke Ophthalmology Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.89%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 21 Aug 202532.27m5.89%
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.